

# J M Schattenberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4418448/j-m-schattenberg-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

168  
papers

6,283  
citations

41  
h-index

75  
g-index

215  
ext. papers

9,683  
ext. citations

6.2  
avg, IF

6.21  
L-index

#	Paper	IF	Citations
168	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. <i>Gut</i> , <b>2022</b> , 71, 156-162	19.2	56
167	Transforming Growth Factor- $\beta$ -Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
166	Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis.. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2022</b> , 101873	2.4	0
165	Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany.. <i>Hepatology Communications</i> , <b>2022</b> ,	6	2
164	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100409	10.3	4
163	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100477	10.3	2
162	Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. <i>Diagnostics</i> , <b>2022</b> , 12, 1069	3.8	
161	Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. AuthorsP reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 673	6.1	1
160	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1547-1558	59.2	50
159	Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 903-909	5.3	2
158	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
157	Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 3179-3185	4	6
156	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , <b>2021</b> , 592, 450-456	50.4	164
155	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , <b>2021</b> , 41, 1227-1242	7.9	20
154	In Reply. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2021</b> , 118, 271-272	2.5	
153	Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249342	3.7	2
152	Health-related quality of life in patients with autoimmune hepatitis. <i>Quality of Life Research</i> , <b>2021</b> , 30, 2853-2861	3.7	0

151	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , <b>2021</b> , 74, 474-482	11.2	16
150	Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	6
149	Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-the role for non-invasive testing. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 214-215	6.1	1
148	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 717-729	24.2	16
147	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1344-1354	13.4	16
146	Risk factors for poorer health literacy in patients with liver cirrhosis. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255349	3.7	1
145	NAFLD between genes and environment: what drives fibrogenesis?. <i>Gut</i> , <b>2021</b> , 70, 815-816	19.2	1
144	Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102706	13.6	7
143	Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 247-253	2.2	1
142	Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2021</b> , 28, 1235-1241	8.6	7
141	Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 829	5.3	1
140	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , <b>2021</b> , 21, 1065-1078	3.8	1
139	Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100317	10.3	5
138	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , <b>2021</b> ,	11.2	8
137	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> , 15, 1253-1266	4.2	3
136	NAFLD in the Elderly. <i>Clinical Interventions in Aging</i> , <b>2021</b> , 16, 1633-1649	4	4
135	Hepatic sarcoidosis: Clinical characteristics and outcome. <i>JHEP Reports</i> , <b>2021</b> , 3, 100360	10.3	1
134	The gut microbiota instructs the hepatic endothelial cell transcriptome. <i>iScience</i> , <b>2021</b> , 24, 103092	6.1	2

133	Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2021</b> , 59, 43-49	1.6	2
132	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	4
131	Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. <i>Visceral Medicine</i> , <b>2020</b> , 36, 411-414	4.4	2
130	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 974-986	3.4	7
129	Liver injury in COVID-19: The current evidence. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 509-519	5.9	108
128	Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1293-1301	6	29
127	NAFLD - sounding the alarm on a silent epidemic. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 377-379	24.2	41
126	Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Nutrients</i> , <b>2020</b> , 12,	6.7	13
125	Patterns of liver injury in COVID-19 - a German case series. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 814-819	5.3	13
124	Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 527-536	6.1	12
123	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. <i>Liver International</i> , <b>2020</b> , 40, 2660	7.9	2
122	Clinical Frailty Scale for risk stratification in patients with SARS-CoV-2 infection. <i>Journal of Investigative Medicine</i> , <b>2020</b> , 68, 1199-1202	2.9	22
121	Differenzialdiagnose der Fettlebererkrankung. <i>Gastroenterologe</i> , <b>2020</b> , 15, 88-95	0.1	
120	Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?. <i>Hepatology Communications</i> , <b>2020</b> , 4, 141-144	6	5
119	Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?. <i>Gastroenterology</i> , <b>2020</b> , 158, 1929-1947.e6	13.3	59
118	Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, 30-38	1.6	2
117	A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, 57-62	1.6	3
116	Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives. <i>Health and Quality of Life Outcomes</i> , <b>2020</b> , 18, 10	3	3

115	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , <b>2020</b> , 158, 1611-1625.e12	13.3	234
114	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 202-209	13.4	764
113	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 680-693	13.4	32
112	Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. <i>Deutsches A&amp;#x0308;rzblatt International</i> , <b>2020</b> , 117, 719-724	2.5	8
111	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 728-735.e4	6.9	73
110	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 816-827	13.4	88
109	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2112-2119	4	35
108	Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC). <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 3006-3013	4	4
107	On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1592-1593	13.4	3
106	The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 1365-1375	5.9	18
105	Impact of non-selective $\beta$ blockers on hepatic encephalopathy in patients with liver cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 82, 83-89	3.9	1
104	Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis. <i>JHEP Reports</i> , <b>2020</b> , 2, 100081	10.3	1
103	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	51
102	Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 942-948	5.3	21
101	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. <i>JHEP Reports</i> , <b>2020</b> , 2, 100168	10.3	7
100	Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1042-1050	6.1	4
99	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , <b>2020</b> , 2, 100163	10.3	20
98	Neue diagnostische Methoden für Patienten mit Diabetes und Fettleber. <i>Diabetologe</i> , <b>2020</b> , 16, 566-572	0.2	

97	Response: Frailty assessment in the COVID-19 pandemic. <i>Journal of Investigative Medicine</i> , <b>2020</b> , 68, 1302-9	5
96	Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1285-1287	13.4 0
95	Intestinal motility: a therapeutic target for NAFLD?. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 957-958	18.8 1
94	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 505-515	13.4 113
93	Nonalcoholic Fatty Liver Disease in 2020. <i>Gastroenterology</i> , <b>2020</b> , 158, 1849-1850	13.3 5
92	Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit. <i>Gut</i> , <b>2020</b> , 69, 1377-1378	19.2
91	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , <b>2019</b> , 1, 188-198	10.3 46
90	Health-related quality of life in patients with compensated and decompensated liver cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 70, 54-59	3.9 18
89	The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 61	4.9 15
88	Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. <i>Journal of Clinical Gastroenterology</i> , <b>2019</b> , 53, e303-e307	3 11
87	Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD. <i>Scientific Reports</i> , <b>2019</b> , 9, 4007	4.9 17
86	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2085-2092.e1	6.9 41
85	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , <b>2019</b> , 68, 1099-1107	19.2 62
84	A novel device for intracolonscopy cleansing of inadequately prepared colonoscopy patients: a feasibility study. <i>Endoscopy</i> , <b>2019</b> , 51, 85-92	3.4 9
83	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 781-793	18.8 29
82	Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 930-939	6.1 36
81	Assessing the disease burden of non-alcoholic fatty liver disease in the real world - big data and big numbers. <i>BMC Medicine</i> , <b>2019</b> , 17, 123	11.4 4
80	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1472-1481	6 18

79	Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1112-1119	6.1	8
78	Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study. <i>Journal of Medical Internet Research</i> , <b>2019</b> , 21, e11250	7.6	9
77	Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 17463	4.9	12
76	Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 764-770	0.7	21
75	Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 60, 96-100	3.9	12
74	Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis. <i>Gastroenterology</i> , <b>2019</b> , 156, 692-707.e7	13.3	15
73	Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. <i>Hepatology</i> , <b>2019</b> , 69, 2241-2257	11.2	107
72	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. <i>Journal of Human Genetics</i> , <b>2018</b> , 63, 621-626	4.3	25
71	Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 986-995	13.4	62
70	Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Digestive Diseases</i> , <b>2018</b> , 36, 78-88	3.2	4
69	Serological diagnosis of early HCC in NASH: A German multicenter study. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S421-S422	13.4	2
68	Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. <i>International Journal of Cardiology</i> , <b>2018</b> , 271, 296-300	3.2	19
67	Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 313-321	6.1	39
66	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 896-904	13.4	55 <sup>0</sup>
65	Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 55, 57-65	3.9	5
64	Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical Trials. <i>JMIR Research Protocols</i> , <b>2018</b> , 7, e106	2	11
63	Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation. <i>American Journal of Physiology - Renal Physiology</i> , <b>2018</b> , 314, G319-G333	5.1	10
62	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1109-1116	6.1	53

61	Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. <i>BMC Gastroenterology</i> , <b>2017</b> , 17, 26	3	4
60	The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. <i>Hepatology</i> , <b>2017</b> , 66, 666-667	11.2	3
59	Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis. <i>Nature Communications</i> , <b>2017</b> , 8, 15069	17.4	13
58	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S593	13.4	7
57	Epidemiology of hepatic encephalopathy in german hospitals - the EpHE study. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2017</b> , 55, 741-747	1.6	12
56	Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu. <i>Cell Death and Disease</i> , <b>2017</b> , 8, e2893	9.8	10
55	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , <b>2017</b> , 60, 1873-1882	10.3	51
54	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. <i>Journal of Lipid Research</i> , <b>2017</b> , 58, 247-255	6.3	108
53	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 740-751	0.7	273
52	Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF- $\kappa$ B activation. <i>Oncotarget</i> , <b>2017</b> , 8, 56095-56109	3.3	7
51	Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. <i>Oncotarget</i> , <b>2017</b> , 8, 115667-115680	3.3	12
50	Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 1188-1197	13.4	10
49	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. <i>BMC Cancer</i> , <b>2016</b> , 16, 94	4.8	32
48	Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. <i>Gut</i> , <b>2016</b> , 65, 1564-71	19.2	75
47	Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw011	1	45
46	Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 291-7	3.3	31
45	The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151200	3.7	16
44	Prädiktion fortgeschrittener Fibrose bei Patienten mit nicht-alkoholischer Fettleber (NAFLD) □ Vergleich von NAFLD fibrosis score (NFS), Fibrosis-4 (Fib-4) score und APRI. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6	



43	Presence of the MBOAT7 rs641738 variant might enhance liver fibrosis in patients with fatty liver: analysis of the German NAFLD CSG cohort. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6	
42	Generation and functional analyses of hepatocyte-specific type I interleukin-1 receptor (IL-1RI) knockout mice. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6	
41	Fruktose [Freund oder Feind?]. <i>Aktuelle Ernährungsmedizin Klinik Und Praxis</i> , <b>2016</b> , 41, 388-402	0.3	
40	Derzeit bleiben als Gegenmittel nur Aufmerksamkeit und Lebensstilmodifikation. <i>Info Diabetologie</i> , <b>2015</b> , 9, 28-32	0	
39	Acute organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors. <i>Cell Death and Differentiation</i> , <b>2015</b> , 22, 826-37	12.7	10
38	Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. <i>BMC Gastroenterology</i> , <b>2015</b> , 15, 97	3	18
37	New onset of diabetes after transplantation is associated with improved patient survival after liver transplantation due to confounding factor. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 439-44	3.9	10
36	TNF signaling <b>2015</b> , 186-202		2
35	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2015</b> , 15, 210	4.8	62
34	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 515-22	4.9	9
33	Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma--a report of 2 cases. <i>Oncology Research and Treatment</i> , <b>2014</b> , 37, 674-7	2.8	5
32	Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 67-71	3.3	7
31	Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling. <i>Redox Biology</i> , <b>2014</b> , 3, 7-15	11.3	45
30	Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28 Suppl 1, 68-76	4	170
29	Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. <i>Transplant International</i> , <b>2013</b> , 26, 67-74	3	48
28	Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. <i>International Journal of Oncology</i> , <b>2013</b> , 42, 1297-304	4.4	35
27	Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2013</b> , 25, 1259-70	2.2	7
26	Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells. <i>Cell Death and Disease</i> , <b>2013</b> , 4, e712	9.8	27

25	Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. <i>BMC Cancer</i> , <b>2012</b> , 12, 109	4.8	77
24	Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , <b>2012</b> , 54, 93-5	14.5	44
23	The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. <i>Free Radical Biology and Medicine</i> , <b>2012</b> , 52, 1911-7	7.8	14
22	Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. <i>American Journal of Physiology - Renal Physiology</i> , <b>2012</b> , 303, G498-506	5.1	22
21	Predictors of the Metabolic Syndrome after Orthotopic Liver Transplantation Identified by a Retrospective Analysis. <i>Transplantation</i> , <b>2012</b> , 94, 673	1.8	
20	Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. <i>European Journal of Internal Medicine</i> , <b>2011</b> , 22, 305-10 <sup>3.9</sup>		25
19	Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1272-80	13.4	50
18	Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26 Suppl 1, 213-9	4	85
17	Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. <i>Current Opinion in Lipidology</i> , <b>2011</b> , 22, 479-88	4.4	86
16	Animal models of non-alcoholic steatohepatitis: of mice and man. <i>Digestive Diseases</i> , <b>2010</b> , 28, 247-54	3.2	114
15	Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). <i>European Journal of Internal Medicine</i> , <b>2010</b> , 21, 208-15	3.9	17
14	TNF/TNF Receptors <b>2010</b> , 161-177		4
13	Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. <i>American Journal of Physiology - Renal Physiology</i> , <b>2009</b> , 297, G907-17	5.1	49
12	Shortcut to death. <i>Hepatology</i> , <b>2009</b> , 50, 2040-3	11.2	2
11	Diabetes and apoptosis: liver. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2009</b> , 14, 1459-71	5.4	30
10	Risk factors in patients with rapid recurrent hepatitis C virus-related cirrhosis within 1 year after liver transplantation. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 2549-56	1.1	14
9	Show me your signaling--and IRL tell you who you are. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 638-9	13.4	2
8	JNK1 but not JNK2 promotes the development of steatohepatitis in mice. <i>Hepatology</i> , <b>2006</b> , 43, 163-72	11.2	306

7	Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. <i>Oncology Reports</i> , <b>2006</b> , 15, 227-30	3.5	58
6	Apoptosis in liver disease. <i>Liver International</i> , <b>2006</b> , 26, 904-11	7.9	87
5	Leptomeningeal familial amyloidosis: A rare differential diagnosis of leptomeningeal enhancement in MRI. <i>Journal of Neurology</i> , <b>2006</b> , 253, 1238-40	5.5	6
4	Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. <i>Hepatology</i> , <b>2005</b> , 42, 1072-81	11.2	62
3	Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 9887-94	5.4	153
2	Hepatocyte resistance to oxidative stress is dependent on protein kinase C-mediated down-regulation of c-Jun/AP-1. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 31089-97	5.4	64
1	CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. <i>Hepatology</i> , <b>2004</b> , 39, 444-55	11.2	60